Ultragenyx Pharmaceutical Inc. (RARE)
| Market Cap | 2.22B |
| Revenue (ttm) | 673.00M |
| Net Income (ttm) | -575.00M |
| Shares Out | 96.43M |
| EPS (ttm) | -5.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,668,336 |
| Open | 22.54 |
| Previous Close | 23.39 |
| Day's Range | 22.51 - 23.19 |
| 52-Week Range | 18.41 - 43.22 |
| Beta | 0.16 |
| Analysts | Strong Buy |
| Price Target | 66.32 (+188.1%) |
| Earnings Date | Feb 12, 2026 |
About RARE
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment... [Read more]
Financial Performance
In 2025, Ultragenyx Pharmaceutical's revenue was $673.00 million, an increase of 20.18% compared to the previous year's $560.00 million. Losses were -$575.00 million, 1.05% more than in 2024.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for RARE stock is "Strong Buy." The 12-month stock price target is $66.32, which is an increase of 188.10% from the latest price.
News
Ultragenyx Pharmaceutical Inc. (RARE) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Securities Fraud: Contact Berger Montague To Discuss Your Rights
Philadelphia, Pennsylvania--(Newsfile Corp. - February 24, 2026) - National plaintiffs' law firm Berger Montague PC announces that a class action lawsuit has been filed against Ultragenyx Pharmaceutic...
Ultragenyx to Participate at Investor Conferences in March
NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for ser...
Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
PDUFA action date set for August 23, 2026 If approved, DTX401 will be the first treatment to address the underlying cause of GDSIa NOVATO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmace...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
NOVATO, Calif., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rar...
Stockholders Who Lost Money Investing in Ultragenyx Pharmaceutical Inc. Should Contact Robbins LLP for Information About Recovering Their Losses from RARE
SAN DIEGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Ultragenyx Pharmaceutical Inc...
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Q4 2025 Earnings Call Transcript
Why Is Ultragenyx Stock Sinking Friday?
“The year ahead marks an important turning point for the company, as we approach two potential product launches and a pivotal data readout that, together, could significantly accelerate our commercial...
Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update
2025 total revenue of $673 million, Crysvita® revenue of $481 million and Dojolvi® revenue of $96 million
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options If you purchased or acqui...
RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Lawsuit
NEW YORK, Feb. 9, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx Pharmaceutical Inc...
Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)
Data represents up to 8.5 years of follow-up and are consistent across age, dose, and genotype BLA resubmitted to U.S. FDA in January 2026; Company expects up to six-month review period per FDA guidel...
Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA
Company expects up to six-month review period per FDA guidelines New longer-term clinical data demonstrating durable positive brain biochemical and clinical effect for as long as 8.5 years to be pres...
Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies
NEW YORK, Jan. 23, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP is investigating Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE) following the Company's announcement of topline results from its Phase III ...
Ultragenyx: From Bone To Brain, Capitulation Creates A Free Option On The Neuro Pipeline
Ultragenyx is rated BUY with a $55 price target, offering 145% implied upside after a sharp post-trial selloff. RARE's commercial base, anchored by Crysvita and Dojolvi, provides a robust revenue safe...
Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
Preliminary 2025 total revenue of $672 million to $674 million, exceeding top end of guidance Preliminary cash and investments of approximately $735 million as of December 31, 2025 Anticipated 2026 c...
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
If approved, DTX401 will be the first therapy approved to treat the underlying cause of GSDIa If approved, DTX401 will be the first therapy approved to treat the underlying cause of GSDIa
Ultragenyx Pharmaceutical, Inc. Investigated by the Portnoy Law Firm
LOS ANGELES, Dec. 30, 2025 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Ultragenyx Pharmaceutical, Inc. (“Ultragenyx" or the "Company") (NASDAQ: RARE) investors that the firm has initiated an inve...
Ultragenyx Bone Drug Stumbles In Phase 3, But Key Catalysts Remain
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) shares plunged 42% on Monday after the company and partner Mereo BioPharma Group plc (NASDAQ: MREO) disclosed disappointing late-stage data for their rare...
These biotech stocks are getting hammered by shocking brittle-bone treatment study results
Shares of both Ultragenyx and Mereo BioPharma were seeing record selloffs after disappointing trial results for setrusumab.
Ultragenyx's bone disease drug fails late-stage trials
Ultragenyx Pharmaceutical said on Monday that its experimental drug for a type of genetic bone disease did not meet the main goal in late-stage studies.
Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta
Neither study achieved its primary endpoint of reduction in annualized clinical fracture rate compared to placebo (Orbit) or bisphosphonates (Cosmic)
AMG Frontier Small Cap Growth Fund: Q3 Sees Strong Outperformance Across Semiconductor Holdings
Our portfolios underperformed during the quarter and trail year to date. Health care was the primary hindrance as a result of our underweight in biotech and negative stock selection. We have materiall...
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript
Ultragenyx Pharmaceutical Inc. (RARE) Presents at Evercore 8th Annual Healthcare Conference Transcript